CFRXQ: AI 评分 47/100 — AI 分析 (4月 2026)

ContraFect Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening and drug-resistant infectious diseases. The company filed for liquidation under Chapter 7 bankruptcy in December 2023.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

ContraFect Corporation, now in Chapter 7 liquidation, focused on developing lysins and antibodies to combat drug-resistant infections, including Staphylococcus aureus and Pseudomonas aeruginosa. Its lead candidate, Exebacase, targeted Staphylococcus aureus, while other programs addressed infections related to biofilms and gram-negative pathogens. The company's future is uncertain due to its bankruptcy filing.

CFRXQ是做什么的？

ContraFect Corporation, established in 2008 and headquartered in Yonkers, New York, was a clinical-stage biotechnology company dedicated to discovering and developing therapeutic protein and antibody products aimed at treating life-threatening and drug-resistant infectious diseases. The company's primary focus was on addressing critical unmet needs in the treatment of severe infections, particularly those caused by antibiotic-resistant bacteria. Its lead program, Exebacase, a novel lysin, had reached Phase III clinical trials and was designed to target Staphylococcus aureus, a common cause of serious infections. In addition to Exebacase, ContraFect was also developing CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials, intended to treat Pseudomonas aeruginosa infections, including ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and surgical site infections. The company also had CF-296 in preclinical development, targeting osteomyelitis and prosthetic joint infections (PJI). Furthermore, ContraFect explored the use of Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. ContraFect's approach involved the development of engineered lysins, such as CF-296, to combat invasive infections caused by Staphylococcus aureus, including biofilm-related infections associated with prosthetic joints, indwelling devices, and osteomyelitis. The company also held a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. However, on December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, casting doubt on the future of its programs.

CFRXQ的投资论点是什么？

ContraFect Corporation's Chapter 7 liquidation filing on December 4, 2023, fundamentally alters any prior investment thesis. The company's pipeline, including Exebacase in Phase III trials for Staphylococcus aureus infections and CF-370 in Phase 1 for Pseudomonas aeruginosa, no longer presents a viable investment opportunity. The company's market capitalization of $0.00B reflects its current state. Any potential value recovery for shareholders is highly speculative and contingent on the bankruptcy proceedings.

CFRXQ在哪个行业运营？

ContraFect Corporation operated within the biotechnology industry, which is characterized by high risk and high reward. Companies in this sector focus on developing innovative therapies for various diseases. The competitive landscape is intense, with numerous companies vying for market share. ContraFect's focus on anti-infectives, particularly lysins, placed it in a niche segment of the broader biotechnology market. However, the company's bankruptcy underscores the challenges faced by smaller biotech firms in securing funding and navigating the regulatory approval process. The bankruptcy of ContraFect highlights the volatility and risk inherent in the biotechnology industry.

Biotechnology

Healthcare

CFRXQ有哪些增长机遇？

Growth opportunity 1: Prior to its bankruptcy, ContraFect aimed to capitalize on the increasing prevalence of antibiotic-resistant infections. The rise of superbugs like MRSA and Pseudomonas aeruginosa presented a significant market opportunity for novel anti-infective therapies. Exebacase, targeting Staphylococcus aureus, had the potential to address a critical unmet need in this area. The global market for antibacterial drugs was projected to reach billions of dollars, offering substantial revenue potential for successful therapies. However, with the company's liquidation, these opportunities are no longer viable.
Growth opportunity 2: ContraFect's development of CF-370, targeting Pseudomonas aeruginosa infections, represented another potential growth avenue. Pseudomonas aeruginosa is a common cause of hospital-acquired infections, including ventilator-associated pneumonia and bloodstream infections. The market for therapies targeting Pseudomonas aeruginosa is substantial, driven by the increasing incidence of these infections and the limited treatment options available. However, the company's bankruptcy has halted the development of CF-370, eliminating this potential growth opportunity.
Growth opportunity 3: The company's research into lysins for treating biofilm-related infections in prosthetic joints and indwelling devices offered a unique growth opportunity. Biofilms are notoriously difficult to eradicate with conventional antibiotics, making them a significant challenge in healthcare settings. ContraFect's CF-296, an engineered lysin, had the potential to address this unmet need. The market for therapies targeting biofilm-related infections is growing, driven by the increasing use of medical devices and the aging population. However, the bankruptcy has suspended the development of CF-296.
Growth opportunity 4: ContraFect's license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens represented a long-term growth opportunity. Gram-negative bacteria are a major cause of antibiotic-resistant infections, and new therapies are urgently needed. This collaboration had the potential to expand ContraFect's pipeline and address a significant unmet need in the anti-infectives market. However, the future of this collaboration is uncertain due to ContraFect's bankruptcy.
Growth opportunity 5: The exploration of Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients presented a potential growth opportunity during the pandemic. COVID-19 patients were at increased risk of secondary bacterial infections, including MRSA bacteremia. Exebacase had the potential to improve outcomes in these patients. However, with the waning of the pandemic and the company's bankruptcy, this opportunity is no longer relevant.

ContraFect Corporation filed for Chapter 7 liquidation on December 4, 2023, effectively halting its operations.
The company's lead program, Exebacase, was in Phase III clinical trials targeting Staphylococcus aureus infections before the bankruptcy filing.
ContraFect was developing CF-370, an anti-bacterial therapeutic candidate, in Phase 1 clinical trials for Pseudomonas aeruginosa infections.
The company's market capitalization is $0.00B, reflecting its current financial distress.
ContraFect had a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.

CFRXQ提供哪些产品和服务？

Discovered and developed therapeutic protein and antibody products.
Focused on treating life-threatening and drug-resistant infectious diseases.
Developed Exebacase, a lysin in Phase III clinical trials for Staphylococcus aureus infections.
Developed CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials for Pseudomonas aeruginosa infections.
Developed CF-296 for osteomyelitis and prosthetic joint infections (PJI).
Explored Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients.
Developed engineered lysins for treating invasive infections caused by Staphylococcus aureus, including biofilm-related infections.
Maintained a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.

CFRXQ如何赚钱？

Focused on discovering and developing novel anti-infective therapies.
Out-licensed or partnered its therapeutic candidates with larger pharmaceutical companies for commercialization.
Relied on venture capital and public offerings to fund its research and development activities.

Hospitals and healthcare providers treating patients with severe bacterial infections.
Patients suffering from life-threatening and drug-resistant infections.
Pharmaceutical companies seeking to expand their anti-infective portfolios through licensing or partnerships.

Proprietary lysin technology platform for developing novel anti-infective therapies.
Patent protection for its lead therapeutic candidates, including Exebacase and CF-370.
Clinical data supporting the efficacy and safety of its therapeutic candidates.

CFRXQ的主要风险是什么？

Ongoing: Chapter 7 bankruptcy proceedings.
Potential: Complete loss of investment for shareholders.
Potential: Delisting from the OTC market.
Potential: Legal and regulatory challenges.
Potential: Inability to revive the company's operations.

CFRXQ的核心优势是什么？

Proprietary lysin technology platform.
Clinical-stage therapeutic candidates targeting drug-resistant infections.
License agreement with The Rockefeller University.
Focus on addressing unmet needs in the anti-infectives market.

CFRXQ的劣势是什么？

Chapter 7 bankruptcy filing.
Limited financial resources.
Dependence on external funding.
High regulatory hurdles for drug approval.

CFRXQ有哪些机遇？

Potential for licensing or partnering its therapeutic candidates.
Growing market for anti-infective therapies due to increasing antibiotic resistance.
Expansion of its pipeline through collaborations and acquisitions.
Development of novel therapies targeting biofilm-related infections.

CFRXQ面临哪些威胁？

Competition from larger pharmaceutical companies.
Failure to obtain regulatory approval for its therapeutic candidates.
Patent expirations.
Changes in healthcare regulations.

CFRXQ的竞争对手是谁？

Adynxx, Inc. — Focuses on pain therapeutics. — (ADYX)
BIMI International Medical Inc. — Healthcare products and services. — (BIMI)
Dmk Petroleum Corporation — Energy sector; not a direct competitor. — (DMKPQ)
eFFECTOR Therapeutics, Inc. — Develops cancer therapies. — (EFTR)
Greenpro Capital Corp. — Business advisory and investment. — (GRPI)

Key Metrics

MoonshotScore: 47/100

Company Profile

Headquarters: Yonkers, US
Employees: 23
Founded: 2014

AI Insight

AI analysis pending for CFRXQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does ContraFect Corporation do?

ContraFect Corporation was a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases. Its primary focus was on developing lysins, such as Exebacase, to target bacteria like Staphylococcus aureus. However, the company filed for Chapter 7 liquidation in December 2023, halting its operations and development programs. The company's assets are now subject to the bankruptcy proceedings.

What do analysts say about CFRXQ stock?

Given ContraFect Corporation's Chapter 7 bankruptcy filing, there is currently no active analyst coverage or consensus on the stock. The company's financial distress and liquidation proceedings render traditional valuation metrics and growth considerations irrelevant. Any prior analyst ratings or price targets are no longer applicable. Investors should be aware that the stock is highly speculative and carries a significant risk of complete loss of investment.

What are the main risks for CFRXQ?

The primary risk for CFRXQ is the ongoing Chapter 7 bankruptcy proceedings, which pose a significant threat to shareholders. The company's assets are being liquidated, and there is a high probability that shareholders will experience a complete loss of their investment. Additional risks include delisting from the OTC market, potential legal and regulatory challenges, and the inability to revive the company's operations. Investors should exercise extreme caution and be fully aware of the risks associated with investing in a bankrupt company.